Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration

BASIC RESEARCH

Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration

Gabriela Bombarda^I; João Paulo J. Sabino^I; Carlos Alberto A. da Silva^I; Rubens Fazan Jr.^I; Maria Cristina O. Salgado^II; Helio C. Salgado^I

^IDepartment of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, SP, Brazil

^IIPharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, SP, Brazil. Ribeirão Preto, SP, Brazil

ABSTRACT

INTRODUCTION: Results from our laboratory have demonstrated that intracerebroventricular administration of sildenafil to conscious rats promoted a noticeable increase in both lumbar sympathetic activity and heart rate, with no change in the mean arterial pressure. The intracerebroventricular administration of sildenafil may have produced the hemodynamic effects by activating sympathetic preganglionic neurons in the supraspinal regions and spinal cord. It is well documented that sildenafil increases intracellular cGMP levels by inhibiting phosphodiesterase type 5 and increases cAMP levels by inhibiting other phosphodiesterases.

OBJECTIVE: To examine and compare, in conscious rats, the hemodynamic response following the intrathecal administration of sildenafil, 8-bromo-cGMP (an analog of cGMP), forskolin (an activator of adenylate cyclase), or dibutyryl-cAMP (an analog of cAMP) in order to elucidate the possible role of the sympathetic preganglionic neurons in the observed hemodynamic response.

RESULTS: The hemodynamic responses observed following intrathecal administration of the studied drugs demonstrated the following: 1) sildenafil increased the mean arterial pressure and heart rate in a dose-dependent manner, 2) increasing doses of 8-bromo-cGMP did not alter the mean arterial pressure and heart rate, 3) forskolin did not affect the mean arterial pressure but did increase the heart rate and 4) dibutyryl-cAMP increased the mean arterial pressure and heart rate, similar to the effect observed following the intrathecal injection of the highest dose of sildenafil.

CONCLUSION: Overall, the findings of the current study suggest that the cardiovascular response following the intrathecal administration of sildenafil to conscious rats involves the inhibition of phosphodiesterases other than phosphodiesterase type 5 that increase the cAMP level and the activation of sympathetic preganglionic neurons.

Keywords: Sympathetic preganglionic neurons; Lumbar sympathetic activity; Forskolin; Phosphodiesterase 5; Spinal cord.

INTRODUCTION

Previous results from our laboratory have demonstrated that the administration of sildenafil into the left lateral ventricle of conscious rats elicited a marked increase in the lumbar sympathetic activity associated with tachycardia but no change in the arterial pressure.¹ The intracerebroventricular administration of sildenafil may have produced sympathetic overactivity in the spinal cord, thereby activating sympathetic preganglionic neurons (SPNs) in addition to supraspinal areas, such as the rostral ventrolateral medulla, circumventricular organs (subfornical organ, organum vasculosum lamina terminalis, and area postrema) and hypothalamic sites controlling the sympathetic drive.^2-5 Thus, the increase in lumbar sympathetic activity and tachycardia observed in conscious rats following the administration of sildenafil into the left lateral ventricle may be explained by an effect in the spinal cord that is probably mediated by SPN activation.¹ Therefore, in order to test the hypothesis that sildenafil is able to directly activate the SPNs and cause a hemodynamic response, the first goal of the present study was to examine, in conscious rats, the effects of sildenafil on the mean arterial pressure (MAP) and heart rate (HR) following intrathecal administration.

Sildenafil increases intracellular cGMP levels via inhibition of phosphodiesterase type 5 (PDE5).^6-11 Moreover, sildenafil can inhibit other phosphodiesterases, including those that preferentially degrade cGMP, cAMP, or both depending on the dose. The inhibition of phosphodiesterases leads to an increase in the intracellular cAMP level.^12-15 In anesthetized rats, a dose-dependent increase in the MAP following the intrathecal administration of an cGMP analog (8-bromo-cGMP) has been observed. A 8-bromo-cGMP-dependent increase in the MAP suggests that the mechanism underlying this increase involves cGMP.¹⁶

As the hemodynamic response caused by sildenafil may involve a lack of cGMP degradation, the second goal of this study was to evaluate the hemodynamic effects of the intrathecal administration of 8-bromo-cGMP in conscious rats and to compare the results with the sildenafil-induced hemodynamic response. Moreover, several studies have proposed that sildenafil, by itself, increases the levels of cAMP.^13-15 After taking this idea into account, the final objective of the present study was to examine the cardiovascular response of conscious rats following the intrathecal administration of forskolin, a direct activator of adenylate cyclase that increases the intracellular levels of cAMP, and dibutyryl-cAMP, an analog of cAMP, and to compare the results with the sildenafil-induced response.

MATERIAL AND METHODS

Animals

All experiments were performed on male Wistar rats (320 + 30 g) housed individually with free access to food and water. The rats were maintained on a 12:12 h light-dark cycle. The experimental protocols used in this research were approved by the Committee of Ethics in Animal Research of the School of Medicine of Ribeirão Preto, University of Sao Paulo (protocol 199/2008).

Surgical procedures

The rats were anesthetized with tribromoethanol (250 mg/kg, i.p., Sigma Aldrich) and underwent a two-stage surgery. Initially, a polyethylene cannula PE-10 (~15 cm long, total volume 10 µL) filled with heparinized saline (pH 7.4) was inserted through the intervertebral space (L5-L6) into the spinal subarachnoid space in a cranial direction (2 cm). The cannula was then implanted using the method reported by Prado et al.¹⁷ with a slight modification developed by Storkson et al.¹⁸ Once the procedure was completed, the animals were allowed five days to recover. On the day before the experiment, polyethylene tubing was inserted into the left femoral artery for direct measurement of the arterial pressure. The experiments were performed in conscious rats 24 hours after femoral artery catheterization.

Measurement of arterial pressure

During the experiments, silence was maintained to avoid undue stress on the animals. The pulsatile arterial pressure was recorded by connecting the arterial catheter to a pressure transducer (P23Gb, Statham, Hato Hey, PR) and was continuously sampled (2 kHz) using an IBM/PC equipped with an analog-to-digital interface (DI-220 Dataq Instruments, Akron, OH). The pulsatile arterial pressure recordings were then analyzed using the CODAS software (Dataq Instruments, Akron, OH) to obtain the MAP and HR values.

Experimental protocols

The animals received an single intrathecal dose (10 | L) of sildenafil (100 µg, n = 7; 10 µg, n = 6; 1 µg, n = 4; 0.1 µg, n = 3), 8-bromo-cGMP (0.03 pig, n = 3; 0.47 pig, n = 6; 1.4 pg, n = 7), forskolin (100 µg, n = 7), dibutyryl-cAMP (100 µg, n = 4) or vehicle (1% DMSO, n = 6). The drugs and vehicle (10 | L) were administered via the intrathecal cannula using a Hamilton microsyringe. After drug administration, an additional 10 µL of aCSF was injected to clear the catheter of the drug solution. At the end of the experiment, 10 µL of Evan's blue was injected into the subarachnoid space. The rats were then anesthetized with tribromoethanol (250 mg/kg, i.p.) and perfused through the heart with 4% paraformaldehyde in 0.1 M phosphate buffered saline. Finally, a necropsy was performed to confirm the position of the intrathecal catheter and to determine how far the dye spread within the subarachnoid space.^17,19

Drugs

The drugs used in the current study were sildenafil citrate (Pfizer), 8-bromo-cGMP (8-bromoguanosine 3',5'-cyclico-monophosphate sodium salt), dibutyryl-cAMP (N6,2'-O-dibutyryladenosine 3' ,5' -cyclic monophosphate sodium salt), and forskolin (Sigma-Aldrich). The vehicle used was DMSO (dimethyl sulfoxide). The components of the aCSF were 127 mM NaCl, 1.9 mM KCl, 1.2 mM KH₂PO₄, 2.4 mM CaCl2, 1.3 mM MgSO4, 26 mM NaHCO3 and 10 mM D- glucose (Sigma-Aldrich). All drugs were dissolved in 1% DMSO immediately before administration, and the pH of the drug solutions was adjusted to 7.4.

Statistical analysis

The results are expressed as the mean + SEM. Comparisons were performed using one-way and two-way analysis of variance (ANOVA) tests followed by a post-hoc Newman-Keuls test. The statistical differences were considered significant at p<0.05.

RESULTS

Basal MAP and HR.

The baseline MAP and HR in rats that received an intrathecal administration of sildenafil, 8-bromo-cGMP, forskolin, dibutyryl-cAMP, or vehicle (DMSO) were similar (Table 1).

Effects of intrathecal administration of sildenafil on the MAP and HR

Intrathecal sildenafil administration elicited a dose-dependent increase in the MAP and HR (Figure 1). Although the maximal pressor and tachycardic response induced by 100 and 10 | g of sildenafil were similar, there was a considerable delay in the maximal response with the lower dose.

Effects of intrathecal administration of 8-bromo-cGMP on the MAP and HR.

The intrathecal administration of different doses of the membrane-permeable analogue of cGMP, 8-bromo-cGMP or its vehicle, DMSO, did not affect the MAP or HR (Figure 2).

Effects of intrathecal administration of forskolin and dibutyryl-cAMP on the MAP and HR.

The administration of forskolin did not affect the MAP but did increase the HR, while the membrane-permeable cAMP analog, dibutyryl-cAMP, induced a rapid and significant increase in both the MAP and HR (Figure 3).

DISCUSSION

The major findings of this study indicate that the intrathecal administration of sildenafil in conscious rats results in a dose-dependent increase in the MAP combined with tachycardia that is unrelated to cGMP action as the administration of a cGMP analog (8-bromo-cGMP) had no effect. In addition, a direct activator of adenylate cyclase (forskolin) increased the HR but did not affect the MAP. In contrast, a cAMP analog (dibutyryl-cAMP) increased the MAP and HR, similar to the increase observed following the administration of 100 µg sildenafil.

One possible explanation for the results observed following the intrathecal administration of sildenafil is the activation of SPNs located in the intermediolateral column of the spinal cord that predominantly innervate the heart and blood vessels. The hemodynamic response obtained with 10 and 1 µg of sildenafil indirectly support this hypothesis, as the increase in the MAP and HR was delayed when compared to results observed after the administration of 100 | g of the drug. The magnitude of the hemodynamic response was comparable even though the doses differed. A possible explanation for this delay may be that lower doses of sildenafil require a longer time to achieve the effective concentration required for the activation of SPNs located deep inside the spinal cord. In fact, an increase in sympathetic activity has been observed in humans after only a single dose of sildenafil.^20,21 In addition, a study recently conducted in our laboratory¹ has indicated that the intracerebroventricular administration of sildenafil in rats causes a noticeable increase in lumbar sympathetic activity without an accompanying change in the MAP.

To fully understand the implications for human health, the hemodynamic effects caused by the intrathecal administration of sildenafil in conscious rats observed in this study necessitate comparison with similar studies in humans. In a study by Philips et al.²⁰ in which healthy males received oral sildenafil, sildenafil had no effect on the MAP and HR but did elicit a significant increase in muscle sympathetic nerve activity. Despite the absence of hemodynamic changes (arterial pressure and heart rate), the findings of the previous researchers²⁰ demonstrate that sildenafil was able to promote sympathetic activation. However, a study recently conducted by our laboratory¹ demonstrated that intracerebroventricular administration of sildenafil (100 µg/ 5 µL) results in a noticeable increase in lumbar sympathetic activity without an accompanying change in the MAP. This contrasts with the significant tachycardia observed in the aforementioned Philips study.²⁰

In the current study, the MAP and HR were unaffected by the intrathecal administration of increasing doses of 8-bromo-cGMP. Conversely, Malik et al.¹⁶ performed intrathecal administration of 8-bromo-cGMP in anesthetized rats, with the same doses used in the present study, and observed a dose-dependent increase in the MAP. However, it should be noted that the results of the current study were obtained using conscious rats, without the use of anesthesia and its associated detrimental effects. One possible explanation for the absence of any cardiovascular effects following the 8-bromo-cGMP injection is that this compound can act directly on high conductance potassium channels in the cell membrane, thereby promoting hyper-polarization of the cell and decreasing their excitability.²² Therefore, the possible excitatory effect of 8-bromo-cGMP could be antagonized by its direct action on potassium channels, masking any possible activation of SPNs and blunting the hemodynamic response. Finally, it is reasonable to hypothesize that the increase in the MAP and HR caused by the intrathecal administration of sildenafil are not mediated by cGMP. There is evidence that sildenafil can interfere with cAMP activity and inhibit the activity of other PDEs.^12-15 It is well known that drug selectivity, dose and route of administration, distribution, pharmacokinetics and the extent of activation of the NO-cGMP pathway are important mechanisms determining the functional role of sildenafil.²³ Bischoff¹² observed that sildenafil has different inhibitory activity against the 11 families of PDEs. It is possible that the dose of sildenafil used in the present study inhibited not only PDE5 but also other PDEs, including those PDEs that preferentially degrade cGMP, cAMP, or both. Therefore, the additional treatments used in the current study aimed to verify a possible role of cAMP in the hemodynamic response promoted by sildenafil. To accomplish this, the rats were intrathecally injected with a direct activator of adenylate cyclase (forskolin) or a membrane-permeable analogue of cAMP (dibutyryl-cAMP). The intrathecally injected forskolin had no effect on the MAP but increased the HR. However, the intrathecally injected dibutyryl-cAMP increased the MAP and the HR, an effect similar to sildenafil, suggesting that cAMP may be involved in the mechanism underlying the cardiovascular effects of sildenafil. Uckert et al.¹⁴ observed that both forskolin and sildenafil administered independently caused the relaxation of isolated human corpus cavernosum tissue. However, this effect was reversed by PKA-I (a cAMP-dependent kinase inhibitor) and PKG-I (a cGMP-dependent kinase inhibitor) in both cases. These findings suggest that cross-regulation may exist between the cyclic nucleotides cAMP and cGMP. The results of the current study are in line with those of Stief et al.,²⁴ who observed that the administration of increasing concentrations of sildenafil in isolated human corpus cavernosum tissue did not modify the cGMP levels in the tissue, although it did increase the cAMP levels. Similarly, increasing concentrations of sildenafil administered to isolated human heart muscle did not alter the cGMP levels, although an increase in the cAMP levels was evident.²⁴ In addition, the findings of Stief et al.²⁴ demonstrate that milrinone, a PDE3-specific inhibitor, causes an increase in the intracellular cAMP levels without altering the cGMP levels, as PDE3 preferentially degrades cAMP. In addition, Botha et al.²⁵ verified that while the serum levels of cAMP increase after the administration of two different doses of sildenafil and milrinone, the serum levels of cGMP are not altered.

Overall, the results of the current study strongly suggest that the pressor response and tachycardia observed after the intrathecal administration of sildenafil to conscious rats involves the inhibition of non-PDE5, cAMP-increasing phosphodiesterases that activate sympathetic preganglionic neurons. The hemodynamic response elicited by the intrathecal administration of sildenafil to conscious, freely moving rats may aid in understanding the cardiovascular outcomes associated with the clinical use of this drug.

ACKNOWLEDGMENTS

Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq), and Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Received for publication on April 1, 2011

First review completed on April 20, 2011

Accepted for publication on April 20, 2011

E-mail: [e-mail]

Tel.: [phone]

• 1. Fazan Jr R, Huber DA, Silva CA, Dias da Silva VJ, Salgado MCO, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol. 2008;104:1683-9, doi: 10.1152/japplphysiol.01142. 2007.
• 2. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-46, doi: 10.1038/nrn1902.
• 3. Simms AE, Paton JF, Pickering AE. Disinhibition of the cardiac limb of the arterial baroreflex in rat: a role for metabotropic glutamate receptors in the nucleus tractus solitarii. J Physiol. 2006;575:727-38, doi: 10.1113/ jphysiol.2006.112672.
• 4. Chen QH, Toney GM. Excitability of paraventricular nucleus neurones that project to the rostral ventrolateral medulla is regulated by small-conductance Ca2+-activated K+ channels. J Physiol. 2009;587:4235-47, doi: 10.1113/jphysiol.2009.175364.
• 5. Collister JP, Nahey DB. The cardiovascular response of normal rats to dual lesion of the subfornical organ and area postrema at rest and to chronic losartan. Brain Res.2009;1302:118-24, doi: 10.1016/j.brainres.2009. 09.021.
• 6. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phospho-diesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
• 7. Zusman RM. Cardiovascular data on sildenafil citrate: introduction. Am J Cardiol.1999; 83:1C-2C, doi: 10.1016/S0002-9149(99)00041-7.
• 8. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C-44C, doi: 10.1016/ S0002-9149(99)00046-6.
• 9. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol. 2000; 86:57F-61F, doi: 10.1016/S0002-9149(00)00895-X.
• 10. Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des. 2006;12:3439-57, doi: 10.2174/ 138161206778343064.
• 11. Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M. Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep. 2007;59:150-63.
• 12. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. IntJImpot Res. 2004;16Suppl 1:S11-4.,doi: 10.1038/sj.ijir. 3901208
• 13. Kim NN, Huang Y, Moreland RB, Kwak SS, Goldstein I, Traish A. Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells. Mol Cell Biol Res Commun. 2000;4:10-4, doi: 10.1006/mcbr.2000.0249.
• 14. Uckert S, Hedlund P, Waldkirch E, Sohn M, Jonas U, Andersson KE, et al. Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol. 2004;22:261-6, doi: 10.1007/s00345-003-0394-4.
• 15. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res. 2007;75:303-14, doi: 10.1016/j.cardiores.2007.02.031.
• 16. Malik V, Holobotovskyy VV, Phillips JK, McKitrick DJ, Arnolda LF. Intrathecal cGMP elicits pressor responses and maintains mean blood pressure during haemorrhage in anaesthetized rats. J Physiol. 2007;581: 543-52, doi: 10.1113/jphysiol.2006.125690.
• 17. Prado WA. Antinociceptive potency of intrathecal morphine in the rat tail flick test: a comparative study using acute lumbar catheter in rats with or without a chronic atlanto - occipital catheter. J Neurosci Methods. 2003;129:33-39, doi: 10.1016/S0165-0270(03)00197-3.
• 18. Storkson RV, Kjorsvik A, Tjolsen A, Hole K. Lumbar catheterization of the spinal subarachnoid space in the rat. J Neurosci Methods.1996;65:167-72, doi: 10.1016/0165-0270(95)00164-6.
• 19. Arnolda LF, McKitrick DJ, Llewellyn-Smith IJ, Minson JB. Nitric Oxide limits pressor responses to sympathetic activation in rat spinal cord. Hypertension. 2000;36:1089-92.
• 20. Phillips BG, Kato M, Pesek CA, Winnicki M, Narkiewicz K, Davison D, et al. Sympathetic activation by sildenafil. Circulation. 2000;102:3068-73.
• 21. Piccirillo G, Nocco M, Lionetti M, Moise A, Naso C, Marigliano V, et al. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J. 2002;143:703-10, doi: 10.1067/mhj.2002.121547.
• 22. Choi J, Farley JM. Effects of 8-bromo-cyclic GMP on membrane potential of single swine tracheal smooth muscle cells. J Pharmacol Exp Ther. 1998; 285:588-94.
• 23. Patil CS, Singh VP, Kulkarni SK. Peripheral and central activation of nitric oxide- cyclic GMP pathway by sildenafil. Inflammopharmacology. 2005;13:467-78, doi: 10.1163/156856005774649359.
• 24. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology. 2000;55:146-50, doi: 10.1016/S0090-4295(99)00371-4.
• 25. Botha P, Parry G, Dark JH, Macgowan GA. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant. 2009;28:676-82, doi: 10.1016/j.healun.2009.04.013.

Publication Dates

• Publication in this collection
  30 Aug 2011
• Date of issue
  2011

History

• Reviewed
  20 Apr 2011
• Received
  01 Apr 2011
• Accepted
  20 Apr 2011